STOCK TITAN
  1. Home
  2. News
  3. ACAD

Acadia Pharmaceuticals Inc - ACAD STOCK NEWS

Welcome to our dedicated news page for Acadia Pharmaceuticals (Ticker: ACAD), a resource for investors and traders seeking the latest updates and insights on Acadia Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Acadia Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Acadia Pharmaceuticals's position in the market.

News
Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 8, 2024
Rhea-AI Summary
Acadia Pharmaceuticals (Nasdaq: ACAD) will announce its first quarter financial results on May 8, 2024. The company will host a conference call and webcast to discuss financial results and operations. The call will be available on Acadia's website and archived until June 7, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
-
News
Acadia Pharmaceuticals Announces Trofinetide New Drug Submission for Treatment of Rett Syndrome Has Been Accepted for Filing and Priority Review by Health Canada
Rhea-AI Summary
Acadia Pharmaceuticals has announced that Health Canada has accepted the New Drug Submission (NDS) for trofinetide for the treatment of Rett syndrome, granting Priority Review. The submission is supported by positive Phase 3 study results, showing significant improvements in patients. If approved, trofinetide will be the first treatment option for Rett syndrome in Canada.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.01%
Tags
none
-
News
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Acadia Pharmaceuticals announced the grant of inducement awards to new employees under the 2023 Inducement Plan. The awards include non-qualified stock options and restricted stock units. Each stock option has an exercise price of $17.73 per share and will vest over four years, while the RSUs will also vest over four years. The awards were granted as inducements material to the new employees' employment, following Nasdaq Listing Rule 5635(c)(4).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.01%
Tags
none
News
Acadia Pharmaceuticals Presents New DAYBUE™ (trofinetide) Clinical Data at the 2024 American Academy of Neurology (AAN) Annual Meeting
Rhea-AI Summary
Acadia Pharmaceuticals presents new DAYBUE™ (trofinetide) clinical data at the 2024 American Academy of Neurology (AAN) Annual Meeting, showcasing outcomes from the DAFFODIL™ study and caregiver interviews in Rett syndrome.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.7%
Tags
clinical trial
-
News
Acadia Appoints Elizabeth H. Z. Thompson, Ph.D. as Executive Vice President, Head of Research and Development
Rhea-AI Summary
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) appoints Dr. Elizabeth H. Z. Thompson as Executive Vice President, Head of Research and Development. Dr. Thompson brings extensive experience in drug research and development, particularly in rare diseases and central nervous system disorders. Her leadership will drive Acadia's growth and pipeline expansion.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.71%
Tags
management
-
News
Acadia Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference
Rhea-AI Summary
Acadia Pharmaceuticals Inc. (ACAD) will participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on April 8, 2024. The event will be held virtually, with a live webcast accessible on Acadia's website and an archived recording available for one month.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.82%
Tags
conferences
News
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Acadia Pharmaceuticals Inc. granted inducement awards to three new employees, including stock options and restricted stock units. The awards were approved by the Compensation Committee and are subject to vesting conditions over four years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.3%
Tags
none
-
News
Acadia Pharmaceuticals to Participate in the UBS Virtual CNS Day
Rhea-AI Summary
Acadia Pharmaceuticals Inc. (ACAD) will take part in the UBS Virtual CNS Day on March 18, 2024. The live webcast of the presentation will be on Acadia's website, with an archived recording available for a month.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.24%
Tags
conferences
-
News
Acadia Pharmaceuticals Announces Top-Line Results from Phase 3 ADVANCE-2 Trial of Pimavanserin in Negative Symptoms of Schizophrenia
Rhea-AI Summary
Acadia Pharmaceuticals Inc. announces disappointing results from the Phase 3 ADVANCE-2 trial evaluating pimavanserin for the treatment of negative symptoms of schizophrenia. Pimavanserin did not show a significant improvement over placebo on the primary endpoint. The safety profile was consistent with previous trials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.2%
Tags
clinical trial
News
Acadia Pharmaceuticals to Participate in TD Cowen’s 44th Annual Health Care Conference on March 6, 2024
Rhea-AI Summary
Acadia Pharmaceuticals Inc. (ACAD) will participate in TD Cowen’s 44th Annual Health Care Conference on March 6, 2024. The presentation will be live webcasted and archived on Acadia's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.13%
Tags
conferences
Stock ACAD logo
Acadia Pharmaceuticals Inc

Nasdaq:ACAD

ACAD Rankings

#1650 Ranked by Market Cap
#572 Ranked by Stock Gains
N/A Ranked by Dividends

ACAD Stock Data

2.81B
109.87M
0.49%
99.56%
6.8%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
San Diego

About ACAD

acadia pharmaceuticals (nasdaq: acad) is a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in related central nervous system (cns) disorders. all of acadia's product candidates emanate from internal discoveries. we believe that they offer innovative therapeutic approaches that may provide significant advantages relative to current therapies. acadia’s history is rooted in science and strong leadership in cns research. our proprietary drug discovery platform has led to a portfolio of drug candidates with large unmet needs. since the beginning, we have been dedicated to discovering, developing and commercializing innovative therapies that improve the lives of patients suffering from such disorders. acadia is headquartered in san diego. the city represents the second largest biotechnology industry cluster in the united states, home to over 400 companies, as well as the salk institute for biological studies